UNIVERSE PHARMACEUTICALS INC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.29 USD | -4.18% |
|
+4.09% | +13.93% |
| 15/04 | Top Premarket Decliners | MT |
| 30/01 | Universe Pharmaceuticals INC Reports Earnings Results for the Full Year Ended September 30, 2023 | CI |
| Sales 2022 | 40.14M 3.35B | Sales 2023 | 32.31M 2.7B | Capitalization | 3.46M 289M |
|---|---|---|---|---|---|
| Net income 2022 | -8M -667M | Net income 2023 | -6M -501M | EV / Sales 2022 | -0.07 x |
| Net cash position 2022 | 14.92M 1.24B | Net cash position 2023 | 13.02M 1.09B | EV / Sales 2023 | -0.3 x |
| P/E ratio 2022 |
-1.41
x | P/E ratio 2023 |
-0.56
x | Employees | 225 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 42.95% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -4.18% | ||
| 1 week | +4.09% | ||
| Current month | +4.57% | ||
| 1 month | +4.57% | ||
| 3 months | +12.25% | ||
| 6 months | +116.04% | ||
| Current year | +13.93% |
1 week
1.91
2.60
1 month
1.572.85
Current year
1.143.00
1 year
0.755.88
3 years
0.7530.00
5 years
0.7571.94
10 years
0.7571.94
| Managers | Title | Age | Since |
|---|---|---|---|
Gang Lai
CEO | Chief Executive Officer | 56 | - |
Lin Yang
DFI | Director of Finance/CFO | 48 | - |
Baochang Liu
COO | Chief Operating Officer | 44 | 01/21/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gang Lai
CEO | Chief Executive Officer | 56 | - |
Lin Yang
DFI | Director of Finance/CFO | 48 | - |
Jiawen Pang
BRD | Director/Board Member | 57 | 01/21/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 2.29 | -4.18% | 95 465 |
| 29/24/29 | 2.39 | +9.63% | 52,850 |
| 26/24/26 | 2.18 | -5.63% | 20,020 |
| 25/24/25 | 2.31 | +7.74% | 147,492 |
| 24/24/24 | 2.144 | -2.54% | 35,261 |
Delayed Quote Nasdaq, April 30, 2024 at 09:37 pm IST
More quotes
Universe Pharmaceuticals Inc is a China-based holding company mainly engaged in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives (TCMD) products targeting the elderly. Through its subsidiary, the Company sells TCMD products, biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces (TCMPs), and dietary supplements manufactured by third-party pharmaceutical companies. Its TCMD products fall into two categories: chronic condition treatments as well as cold and flu medications, including Guben Yanling Pill, Shenrong Weisheng Pill, Fengshitong Medicinal Liquor, Isatis Root Granule and Qiangli Pipa Syrup. Its major customers are pharmaceutical companies, hospitals, clinics and drugstore chains. The Company mainly conducts its businesses within the Chinese market.
Sector
Pharmaceuticals
Calendar
29/07/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +13.93% | 8.66M | |
| +39.33% | 6.01B | |
| -18.38% | 4.4B | |
| -9.17% | 3.17B | |
| +3.98% | 3.07B | |
| -3.41% | 2.51B | |
| +48.74% | 1.88B | |
| -4.82% | 1.73B | |
| -1.24% | 1.65B | |
| -8.96% | 1.58B |
- Stock Market
- Equities
- UPC Stock
